Physicians monitor for side effects, adjust doses, and evaluate response
Small adjustments can kickstart progress
Incorporation of a trifluoromethyl group at the 6-position of the tetrahydropyran ring in omarigliptin (with a (2R, 3S, 5R, 6S) configuration) was found not only to enhance the pharmacokinetic profile in mice but also to maintain robust DPP-4 inhibitory activity
If weekly tirzepatide injections produce double the weight loss of daily orforglipron pills, some people will gladly accept the needle
Insurance coverage will be a challenge if not expanded to include other conditions, one physician said, so FDA approval is paramount. This challenge echoes concerns of patients, who also list high costs as the primary obstacle to GLP-1RA treatment, according to The Cure GLP-1RA Report: Insights from Patients on GLP-1RA Medications and the Future of Obesity Treatment, which reports results of a survey of patients who had taken GLP-1RA medications